Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Subcutaneous Trastuzumab via Different Delivery Platforms
NCT07214766Phase 1Completed
- Sponsor
- Genentech
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of trastuzumab in breast cancer (2 arms), sponsored by Genentech. Primary endpoints: Area Under the Concentration-Time Curve from Hour 0 to 21 days Postdose and Maximum Observed Concentration at Day 57. Started Oct 2025; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07214766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214766.